Diffusion Pharmaceuticals Inc., of Charlottesville, Va., closed its public offering of about 11.4 million shares, together with accompanying common warrants, at a price of 35 cents per share and associated warrants. Gross proceeds are expected to be about $4 million, which will be used to fund research and development of its lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate, including clinical trial activities, and for general corporate purposes. H.C. Wainwright & Co. acted as the exclusive placement.

Halozyme Therapeutics Inc., of San Diego, said it priced $400 million aggregate principal amount of its convertible senior notes due 2024 that are being offered in a private placement to qualified institutional buyers. The company has also granted an option to the initial purchasers to buy up to an additional $60 million of the notes. The net proceeds will be $388.5 million (or approximately $446.9 million if the initial purchasers exercise their option to purchase additional notes in full). It plans to use up to $200 million to repurchase shares of the company's common stock, including up to $143.1 million to repurchase approximately 8.1 million shares of its common stock concurrently with the offering in privately negotiated transactions effected through one or more of the initial purchasers. A further $26.1 million of the net proceeds will repay all outstanding amounts under its loan agreement with Oxford Finance and Silicon Valley Bank, and the remainder of the net proceeds will be used for general corporate purposes.

Lidds AB, of Uppsala, Sweden, has completed a directed issue of 562,500 shares at SEK16 each for proceeds amounting to SEK9 million (US$933,093), before transaction costs.

Nextcure Inc., of Beltsville, Md., said it priced a public offering of 4.07 million shares of its common stock at $36.75 each and granted the underwriters a 30-day option to purchase up to an additional 611,578 shares. Gross proceeds will be approximately $150 million, excluding any exercise of the underwriters' option to purchase additional shares.

Tonix Pharmaceuticals Holding Corp., of New York, said it priced an underwritten public offering with expected total gross proceeds of $9 million. The company said it believes the funding will enable it to regain compliance with the Nasdaq listing rule relating to the stockholders' equity standard, by increasing stockholders' equity to above $10 million.

No Comments